Early Synovitis Detection in Psoriasis Without PsA – Imaging Advances
Subclinical Synovitis in Psoriasis: A Hidden Risk for Psoriatic Arthritis
TOPLINE: Patients with psoriasis, even those without overt signs of psoriatic arthritis (PsA), exhibit a substantially elevated risk of synovitis, a key indicator of joint inflammation. A recent systematic review and meta-analysis reveals that these individuals are more than twice as likely to have synovitis compared to healthy controls.
METHODOLOGY:
This thorough analysis, conducted through October 2024, synthesized data from 12 cross-sectional and case-control studies. The research encompassed a total of 2606 participants, meticulously categorized into three groups: 1593 patients with psoriasis but no reported musculoskeletal involvement, 327 patients diagnosed with PsA, and 686 healthy individuals serving as controls.
The participant demographics were as follows:
Psoriasis without MSK involvement: Mean age 46.4 years, 61.6% male.
PsA: Mean age 50.2 years, 64.2% male.
Healthy controls: Mean age 45.7 years, 48.8% male.
The average duration of psoriasis was 14.8 years for the psoriasis-only group and 9.8 years for the PsA group. Mean Psoriasis Area and Severity Index (PASI) scores were 8.2 and 7.6, respectively, indicating moderate disease severity in both cohorts. The primary outcome measured was the detection of synovitis via imaging in patients with psoriasis compared to those with PsA and healthy controls.
KEY FINDINGS:
The meta-analysis demonstrated a clear association between psoriasis and subclinical joint inflammation:
Increased Synovitis Risk: Patients with psoriasis, irrespective of musculoskeletal symptoms, showed a significantly higher prevalence of synovitis compared to healthy individuals. The risk ratio (RR) for synovitis in this group was 2.55 (P < .001), indicating more than a twofold increased risk. Imaging Modalities: Both ultrasonography (RR, 2.50; P = .03) and MRI (RR, 6.40; P = .003) were effective in detecting synovitis. Notably, MRI demonstrated a substantially higher detection rate for subclinical joint inflammation. Psoriasis vs.PsA: While more patients with PsA presented with synovitis, the difference in the risk for synovitis between patients with psoriasis (without overt PsA) and those with established PsA was not statistically significant (RR, 0.50; P = .19). This suggests that subclinical joint inflammation is a common feature even in the early stages of psoriasis.
IMPLICATIONS FOR CLINICAL PRACTICE:
The findings underscore the potential of imaging techniques to identify individuals with psoriasis who are at a heightened risk of developing PsA. Though, the authors advise a cautious approach to the routine implementation of these tools in clinical practice. Considerations such as the limitations of current imaging protocols, associated costs, and resource requirements are paramount.
“Future longitudinal studies are needed to better characterize the transition from psoriasis to PsA, determine the predictive value of subclinical synovitis, and assess whether early intervention strategies coudl modify disease progression and reduce the risk of PsA growth,” the authors emphasized. this highlights the critical need for further research to refine diagnostic pathways and therapeutic strategies for early PsA intervention.
SOURCE AND DISCLOSURES:
This research was led by Shanti Mehta, BSc, from the University of Toronto, Toronto, Ontario, Canada, and was published online on july 16 in JAMA Dermatology. The authors reported no funding facts. One author disclosed receiving honoraria for speaking engagements from AbbVie, Janssen, Novartis, Sandoz, and Amgen.
LIMITATIONS:
The reviewed studies were subject to several limitations, including non-standardized protocols, variability in imaging and diagnostic criteria, and a relatively homogeneous patient population. The predominance of cross-sectional designs also restricted the ability to establish a definitive temporal link between the presence of synovitis and the progression from psoriasis